Tempest Therapeutics (NASDAQ:TPST) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Tempest Therapeutics (NASDAQ:TPST) announced its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04), FiscalAI reports.

Tempest Therapeutics Stock Performance

Shares of NASDAQ TPST opened at $1.17 on Friday. Tempest Therapeutics has a 1 year low of $0.84 and a 1 year high of $12.23. The firm has a market cap of $18.70 million, a P/E ratio of -0.19 and a beta of -1.72. The stock has a fifty day moving average price of $1.07 and a two-hundred day moving average price of $1.70.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned approximately 0.23% of Tempest Therapeutics at the end of the most recent quarter. Institutional investors own 22.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TPST. Zacks Research cut Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded Tempest Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Monday, July 13th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.